Personalized Treatment for Advanced Combined Liver Cancer
Part of Cancer, Digestive system clinical trials.
This study is for people with a rare and advanced liver cancer called combined hepatocellular cholangiocarcinoma (CHC). Doctors will use information from your tumor and health history to find the best treatment approach for your specific cancer type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have a confirmed diagnosis of a rare liver cancer called combined hepatocellular cholangiocarcinoma (CHC).
- Your cancer must be too advanced to be removed by surgery, or it has spread to other parts of your body. You may have had treatment before, like local therapy or systemic therapy.
- You need to have at least one tumor that can be measured on a scan (a 'measurable lesion').
- Your overall health must be fairly good (ECOG performance status of 0, 1, or 2), meaning you can care for yourself and are up and about more than half of the day.
- Your liver function must be Child-Pugh class A or B, meaning your liver is working reasonably well.
- You must not have had other cancers in the last five years (except some very low-risk types), no major bleeding within the last six months, no organ or bone marrow transplant in the last two years, and no active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus standard chemotherapy (gemcitabine and cisplatin) for people with a rare type of liver cancer that has spread or cannot be removed by surgery. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy (Gemox) with two targeted drugs (anlotinib and sintilimab) for people with a rare type of liver cancer that cannot be removed by surgery or has spread. It may offer a new option for patients who have not had systemic treatment or whose first treatment has stopped working.
This trial tests a combination of two drugs (cadonilimab and capecitabine) given after surgery to prevent your mixed liver cancer (HCC/ICC) from coming back. It is for people whose cancer has been completely removed and who are in good health.
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This trial tests a combination of three treatments for a rare form of liver cancer that is both hepatocellular and cholangiocarcinoma: HAIC (chemotherapy given directly into the liver artery), Camrelizumab (an immunotherapy that helps your immune system attack cancer cells), and Rivoceranib (a targeted therapy that blocks blood vessel growth to tumors). It may be an option if you haven't had prior systemic therapy for this cancer and your liver function is stable.
Hear when a new Combined Hepatocellular-cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.